Rivaroxaban Acute Stroke Safety Study "RASS"


Phase N/A Results N/A

Summary of Purpose

Atrial fibrillation is a common cardiac arrhythmia and a major risk for ischemic stroke. Furthermore the risk of stroke is higher in the first month after transient ischemic attack (TIA)/stroke. Rivaroxaban has been approved by Health Canada over period of last two years for prevention of stroke and have been found equally effective as oral Vitamin K antagonist. The foremost benefits of NOAC are reduced...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 April 2016.

1 Mar 2014 29 Oct 2014 1 Jan 2016 Unavailable 1 Apr 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Probability Sample